Group 1: Company Performance Overview - The company reported a total revenue of 90,833.74 million yuan in the first half of the year, a year-on-year decrease of 12.72% [2] - In Q2, the revenue was 51,753.08 million yuan, showing a quarter-on-quarter growth of 32.43% [2] - The net profit for the first half was 15,358.81 million yuan, down 31.58% year-on-year, with a net profit attributable to shareholders of 13,983.26 million yuan, also down 31.32% [2] Group 2: Product Development and Market Strategy - The company launched several new products in the animal health sector, including vaccines for poultry and swine, and various pet products [3][4] - The newly launched product Mopuxin (a broad-spectrum antiparasitic) has achieved over 10 million yuan in revenue since its release [4] - The company aims to enhance its product matrix in the pet sector, collaborating with strategic partners to strengthen its market presence [5] Group 3: Market Position and Competitive Landscape - The company has developed over 90% of the top 100 domestic pig farming groups, indicating strong market penetration [4] - The high pathogenic avian influenza vaccine generated revenue of 123 million yuan in the first half, down 13.94% year-on-year [6] - The company is focusing on maintaining a competitive edge through cost control and product innovation amidst increasing market competition [7] Group 4: Future Outlook and Strategic Initiatives - The company plans to continue investing heavily in R&D to enhance its core technological capabilities and improve production efficiency [3] - It aims to expand its international presence and become a leading player in the animal health industry [3][5] - The company is also focusing on building a robust ecosystem in the pet industry through strategic partnerships and digital integration [5]

编号：2022-004 证券代码：300119 证券简称：瑞普生物 天津瑞普生物技术股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------------------|----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - Revenue for Q3 2022 reached ¥568,423,568.34, an increase of 24.05% year-over-year[7] - Net profit attributable to shareholders was ¥93,188,240.25, up 5.17% compared to the same period last year[7] - Net profit excluding non-recurring gains and losses was ¥80,725,500.19, a 5.49% increase year-over-year[7] - The company's operating revenue for the period was approximately 1.48 billion CNY, a slight decrease from 1.50 billion CNY in the previous period[40] - The net profit for the current period is ¥256,016,202.77, a decrease of 20% compared to ¥319,799,858.54 in the previous period[45] - The total operating income for the current period is ¥1,375,885,824.91, down from ¥1,472,348,697.81 in the previous period[49] - The operating profit is ¥284,666,735.22, compared to ¥360,731,153.64 in the previous period, reflecting a decline of approximately 21%[49] - The basic earnings per share for the current period is ¥0.5036, down from ¥0.7358 in the previous period[45] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥6,178,265,581.62, reflecting an 8.57% increase from the end of the previous year[7] - The company's total liabilities as of September 30, 2022, were approximately 1.79 billion CNY, compared to 1.37 billion CNY at the beginning of the year[38] - The company's current assets totaled approximately 3.18 billion CNY, up from 3.06 billion CNY at the beginning of the year[32] - The company's long-term equity investments increased to approximately 375.31 million CNY from 275.06 million CNY at the beginning of the year[32] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥200,918,377.93, down 7.10% compared to the previous year[7] - The cash flow from operating activities net amount is ¥200,918,377.93, a decrease from ¥216,285,018.38 in the previous period[49] - The company experienced a net decrease in cash and cash equivalents of ¥659,463,322.36, contrasting with an increase of ¥73,708,871.42 in the previous period[52] - The ending balance of cash and cash equivalents stood at ¥620,788,270.41, down from ¥1,280,251,592.77 at the beginning of the period[52] - Cash inflow from financing activities totaled ¥850,508,517.98, an increase from ¥579,350,000.00 in the prior period[52] - The net cash flow from financing activities was ¥91,993,022.46, a significant improvement from a net outflow of ¥92,423,177.27 previously[52] Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,383, with the top 10 shareholders holding a combined 70.27% of shares[16] - Li Shoujun, a domestic individual, holds 35.78% of shares, amounting to 167,474,479 shares, with 36,100,000 shares pledged[16] - The total number of restricted shares at the beginning of the period was 142,299,928, with 126,575 shares released and 2,813,039 shares added, resulting in 144,986,392 restricted shares at the end of the period[22] - The company completed the cancellation of 43,401 shares from its repurchase account and 70,575 shares from the 2019 restricted stock incentive plan, reducing total shares from 468,132,762 to 468,018,786[24] Investments and Subsidiaries - The company reported a significant increase in trading financial assets, which rose by 113.88% to ¥1,235,994,616.46[13] - Short-term borrowings increased by 40.81% to ¥832,356,433.28, attributed to new loans taken during the period[13] - Investment income dropped by 88.74% to ¥1,598,199.46, primarily due to the disposal of equity in a subsidiary[15] - The company’s subsidiary, Repu (Tianjin) Biopharmaceutical Co., Ltd., obtained two new veterinary drug registration certificates during the reporting period[26] - The company obtained the approval for the new veterinary drug "Duck Tembusu Virus Live Vaccine (FX2010-180P strain)" and has commenced production and sales[27] - The company increased its stake in its subsidiary Hubei Longxiang Pharmaceutical Technology Co., Ltd. by acquiring 1,697,724 shares, representing 1.3849% of Longxiang's total share capital, at an average price of 2.58 CNY per share, totaling approximately 4.38 million CNY[28] Research and Development - The company is actively advancing the production of "Liver and Gallbladder Oral Liquid," a new veterinary drug aimed at treating infectious bronchitis and mycoplasma infections in chickens[27] - The research and development expenses decreased to ¥74,433,917.50 from ¥85,769,408.06 in the previous period, indicating a reduction of approximately 13%[49] Tax and Expenses - The company’s tax expenses for the current period are ¥28,917,651.33, down from ¥38,847,027.97 in the previous period[49] - The total operating costs for the current period are ¥1,215,102,335.32, an increase from ¥1,167,310,849.13 in the previous period[49]

1 证券代码：300119 证券简称：瑞普生物 公告编号：2022-078 天津瑞普生物技术股份有限公司 关于参加"2022 年度天津辖区上市公司半年报业绩说明会与投 资者网上集体接待日"活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司（以下简称"公司"）已于 2022 年 8 月 26 日发布了 2022 年半年度报告，为便于广大投资者更深入全面地了解公司情况， 公司定于 2022 年 9 月 6 日（周二）13:40-16:40 参加由天津证监局主办、天津 上市公司协会、深圳市全景网络有限公司协办的"2022 年度天津辖区上市公司 半年报业绩说明会与投资者网上集体接待日"活动。 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" （http://rs.p5w.net）参与本次互动交流。出席本次活动的人员有：董事长、 总经理李守军先生、财务负责人李改变女士、董事会秘书谢刚先生。 欢迎广大投资者积极参与。 特此公告。 天津瑞普生物技术股份有限公司 董事会 二〇二二年八月三十一日 ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 15%[25]. - The net profit attributable to shareholders was 80 million RMB, up 20% compared to the same period last year[25]. - The company's operating revenue for the reporting period was ¥908,337,389.14, a decrease of 12.72% compared to ¥1,040,707,903.59 in the same period last year[33]. - The net profit attributable to shareholders was ¥139,832,575.93, down 31.32% from ¥203,585,329.13 year-on-year[33]. - The net profit after deducting non-recurring gains and losses was ¥118,805,979.05, reflecting a decline of 33.82% compared to ¥179,532,070.84 in the previous year[33]. - The net cash flow from operating activities was ¥63,888,468.85, a significant drop of 50.51% from ¥129,098,138.94 in the same period last year[33]. - The company reported a significant increase in user data, indicating a growing customer base and market demand for its products[83]. - The company reported a total financial asset value of ¥1,054,122,725.14, with a fair value change gain of ¥10,888,091.72[146]. Market Expansion and Strategy - The company plans to expand its market presence by entering three new provinces in the next fiscal year[25]. - The company aims to cover 1,500 key poultry breeding counties and 1,000 key livestock breeding counties, enhancing its market presence through a dual empowerment model for sales and technical marketing personnel[58]. - The company is focusing on expanding its product line for pets, including anti-parasitic and pain relief medications[50]. - The company is exploring potential mergers and acquisitions to enhance its product offerings and market reach in the veterinary pharmaceutical industry[77]. - The company is focusing on international expansion and attracting high-level talent with an attractive compensation system[114]. Research and Development - Research and development expenses increased by 25% to 50 million RMB, focusing on new vaccine technologies[25]. - The company is investing in research and development for new veterinary drugs and additives to enhance animal health and nutrition[50]. - The company is actively pursuing research and development of new veterinary vaccines and diagnostic kits to strengthen its competitive position in the market[77]. - The company has established multiple R&D platforms, including those for new drug development and vaccine technology, to enhance product competitiveness[124]. - The company is committed to maintaining compliance with regulatory standards for its veterinary products, as evidenced by the recent approvals received[77]. Product Development and Innovation - The company aims to launch two new products in the veterinary medicine sector by the end of 2022[25]. - The company has developed a series of biological safety products for disinfection in animal housing and feeding equipment[50]. - The company launched several new products, including a trivalent inactivated vaccine for avian influenza, which provides effective immune protection against multiple strains[58]. - The company has introduced a new formulation of doxycycline soluble powder and other antibiotics, aiming to meet the growing demand in the veterinary sector[78]. - The company has successfully launched its first genetically engineered subunit vaccine for porcine circovirus type 2, establishing a solid foundation for its genetic engineering expression system platform[18]. Supply Chain and Operational Efficiency - The company has established partnerships with five new distributors to enhance its supply chain efficiency[25]. - The company reported a significant increase in procurement costs due to rising commodity prices, COVID-19, and global inflation, prompting a restructuring of its procurement process to optimize supply chain management[50]. - The company has implemented a centralized procurement strategy to enhance supply chain efficiency and reduce costs, with nine GMP production bases passing the new veterinary GMP acceptance[98]. - The company aims to strengthen supply chain integration by focusing on raw material self-supply and large-scale production, thereby reducing production costs[118]. Financial Management and Investments - The company has no plans to distribute cash dividends or issue bonus shares for this fiscal year[6]. - The company has committed to several investment projects, with a total commitment of CNY 133,600 million, of which CNY 132,202.05 million has been allocated[163]. - The company has obtained new veterinary drug registration for canine parvovirus antiserum and clinical approval for feline and canine vaccines, enhancing its pet vaccine offerings[105]. - The company increased its stake in Longxiang Pharmaceutical to 80.18%, strengthening its integrated competitive advantage in raw materials and formulations[107]. - The company has established a timeline for the approval and market launch of several new veterinary products, ensuring a steady pipeline of innovations[77]. Risks and Challenges - The company is facing risks related to animal epidemics and accounts receivable, which are significant concerns for future operations[5]. - The company acknowledges the long and uncertain R&D cycle for veterinary products, which poses risks in product development and market entry[185]. - The company has implemented a strict credit management policy to mitigate risks associated with accounts receivable[186]. - The company is exposed to animal epidemic risks, which could significantly impact its operational performance and financial results[183].

Financial Performance - Revenue for Q1 2022 was CNY 390,806,576.59, a decrease of 30.20% compared to CNY 559,913,601.19 in the same period last year[2] - Net profit attributable to shareholders was CNY 72,205,916.82, down 37.94% from CNY 116,352,232.21 year-on-year[2] - Basic earnings per share decreased by 46.62% to CNY 0.1564 from CNY 0.2930 in the previous year[2] - Total operating revenue for Q1 2022 was CNY 390,806,576.59, a decrease of 30.2% compared to CNY 559,913,601.19 in the same period last year[28] - Net profit attributable to the parent company for Q1 2022 was CNY 72,205,916.82, a decline of 38.0% from CNY 116,352,232.21 in Q1 2021[29] - The total comprehensive income attributable to the parent company was CNY 72,205,916.82, down from CNY 116,352,232.21 in the previous period, representing a decrease of approximately 38%[30] Cash Flow and Assets - Net cash flow from operating activities was negative CNY 54,538,255.13, a decline of 232.26% compared to CNY 41,237,174.09 in the same period last year[2] - Cash inflow from operating activities totaled CNY 348,762,765.72, a decrease of about 26.5% from CNY 474,225,967.03 in the previous year[34] - Cash outflow from operating activities was CNY 403,301,020.85, down from CNY 432,988,792.94, indicating a reduction of approximately 6.5%[34] - Total assets at the end of the reporting period were CNY 5,618,731,855.50, a decrease of 1.27% from CNY 5,690,781,226.40 at the end of the previous year[2] - As of the end of the reporting period, the company’s total current assets amounted to approximately CNY 2.86 billion, a decrease from CNY 3.06 billion at the beginning of the year[25] - The company’s cash and cash equivalents decreased from CNY 1.31 billion at the beginning of the year to approximately CNY 717 million[25] Investment and R&D - The company invested a total of 33.85 million CNY in R&D, accounting for 8.7% of its revenue[16] - Research and development expenses for Q1 2022 amounted to CNY 21,549,970.45, compared to CNY 24,177,319.41 in the previous year, reflecting a decrease of 10.8%[29] - The company is in the process of applying for product approval numbers for several new veterinary drugs, enhancing its product pipeline and market competitiveness[18] - The company obtained 1 new veterinary drug registration certificate and 34 product approval numbers during the reporting period[16] Shareholder Information - The top shareholder, Li Shoujun, holds 35.76% of the shares, amounting to 167,474,479 shares[9] - The second-largest shareholder, Liang Wu, owns 5.06% of the shares, totaling 23,716,898 shares[9] - The company has a total of 22,844 common shareholders as of the end of the reporting period[9] Market Challenges - The company faced challenges in the pig farming sector due to low prices and reduced demand for pork, leading to ongoing capacity reduction[13] - The poultry farming sector experienced significant capacity reduction due to prolonged losses and rising feed costs[13] Product Development - The company has not reported any new product developments or market expansions in the current quarter[13] - The clindamycin phosphate granules project has received approval, offering a highly effective oral medication for skin wounds and infections in dogs[16] - The compound nystatin ointment project has also received approval, designed to treat various ear conditions in dogs and cats[16] - The imidacloprid and moxidectin topical solution for dogs has been approved, providing a comprehensive solution for 28 types of internal and external parasites[16] - The imidacloprid and moxidectin topical solution for cats has received approval, enhancing the company's product line in the pet healthcare market[16] - The company emphasizes innovation and aims to maintain its leading position in the pet healthcare sector through continuous R&D investment[16] - The new products are expected to significantly enhance the company's competitiveness and market share in the pet healthcare industry[16] Financial Ratios - The company's debt-to-asset ratio stood at 22.4%, indicating a strong financial position[13]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2021, representing a year-on-year growth of 15%[5]. - The net profit attributable to shareholders was 200 million RMB, an increase of 10% compared to the previous year[5]. - The total revenue for 2021 was CNY 2,007,138,304.57, representing a 0.34% increase from CNY 2,000,407,106.41 in 2020[22]. - The net profit attributable to shareholders for 2021 was CNY 412,784,534.66, up 3.66% from CNY 398,196,538.84 in 2020[22]. - The company reported a net profit of CNY 284,612,699.63 after deducting non-recurring gains and losses, which is a slight increase from CNY 284,524,652.70 in 2020[22]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a 20% year-over-year growth[78]. - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming for 1.875 billion RMB[78]. - The company reported a net profit attributable to shareholders of 412.78 million CNY, an increase of 3.66% year-on-year, despite a 5.22% rise in operating costs to 970 million CNY[63]. Research and Development - The company has invested 100 million RMB in R&D for new product development, focusing on innovative veterinary pharmaceuticals[5]. - Research and development expenses increased by 5.52% to 117.69 million CNY, reflecting the company's commitment to enhancing product competitiveness[63]. - The R&D team includes 12 national-level talents and over 70% of researchers hold master's or doctoral degrees, covering various fields such as veterinary medicine and molecular biology[49]. - The company has over 30 new veterinary drugs in clinical evaluation and application stages, indicating a strategic advantage in its R&D pipeline[66]. - The company is committed to independent and collaborative research and development, focusing on new veterinary products that meet market needs to reduce risks from development to market launch[159]. - The company achieved a total R&D investment of ¥151,631,979.07 in 2021, accounting for 7.55% of its operating revenue[112]. - The company is enhancing its R&D capabilities by integrating various technical platforms to develop a diverse product portfolio that meets market demands[69]. Market Expansion and Strategy - Future outlook includes an expected revenue growth of 20% for 2022, driven by market expansion and new product launches[5]. - The company aims to expand its market share in Southeast Asia, targeting a 15% increase in sales from this region by 2023[5]. - The company is exploring potential acquisitions to enhance its market presence and product offerings in the animal health sector[5]. - The company is actively engaging in strategic partnerships to leverage expertise in vaccine development and distribution[31][39]. - The company plans to enhance its market expansion strategies, targeting both domestic and international markets to increase sales and brand recognition[42]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence, particularly in the pet nutrition segment[78]. - The company aims to strengthen its market presence by expanding its distribution channels and increasing production capacity for its new products[28][31]. Product Development and Innovation - The company launched 21 new products in 2021, focusing on multi-valent vaccines and diagnostic solutions for various diseases[67]. - The company has developed multiple innovative drug formulations, including long-acting sustained-release preparations and nano-formulations, filling international gaps in the market[52]. - The company is focusing on the development of innovative vaccines, such as the "副猪嗜血杆菌病三价灭活疫苗" and "猪乙型脑炎活疫苗," to enhance its market position[31][39]. - The company has established a comprehensive technical service system, enhancing its capabilities in disease prevention and control, and providing diversified services to clients[48]. - The company is set to introduce a range of new products for pets, including solutions for ear diseases and joint protection, contributing to its high-quality development[152]. - The company has successfully applied for clinical approval for a gene-deleted inactivated vaccine for pseudorabies in pigs, demonstrating advanced technology and stability[154]. Operational Efficiency and Cost Management - The company faced significant pressure on procurement costs due to rising prices of raw materials, logistics, and energy, influenced by the international trade environment and COVID-19 pandemic[44]. - The company implemented a centralized procurement system to enhance material quality and ensure timely supply, aiming to reduce overall procurement costs[44]. - The company aims to reduce operational costs by 15% through efficiency improvements in the supply chain[196]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization strategies[196]. Risk Management - The company has identified risks including human resource challenges and accounts receivable management, which may impact future performance[5]. - The company acknowledges the risk of animal epidemics affecting the livestock industry, which could lead to significant economic losses, despite improved disease prevention capabilities[161]. - The company has implemented a strict credit management policy for accounts receivable, with most customer debts within normal credit periods, although there remains a risk of uncollectible accounts[160]. - The company has a comprehensive risk management strategy to address various operational risks, including those related to product development and market dynamics[159]. Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder rights and independent operation from its controlling shareholder[169]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[170]. - The company maintains complete independence from its controlling shareholders in terms of business, personnel, assets, and finance, ensuring autonomous operational capabilities[174]. - The company has committed to timely and accurate information disclosure, ensuring all shareholders have equal access to information[171].

Financial Performance - The company's revenue for Q3 2021 was ¥458,238,719.95, a decrease of 14.67% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2021 was ¥88,606,703.01, down 15.59% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥76,522,167.07, a decrease of 22.93% compared to the previous year[3] - The basic earnings per share for Q3 2021 was ¥0.2231, down 15.62% year-on-year[3] - The weighted average return on equity was 3.48%, a decrease of 1.20% compared to the previous year[3] - Operating profit for Q3 2021 was ¥360,731,153.64, up 8.0% from ¥333,863,789.63 in Q3 2020[28] - Net profit attributable to shareholders of the parent company was ¥292,192,032.14, representing a 15.8% increase from ¥252,268,462.31 in the previous year[29] - Basic and diluted earnings per share for Q3 2021 were both ¥0.7358, compared to ¥0.6376 in Q3 2020[29] Assets and Liabilities - Total assets at the end of Q3 2021 reached ¥4,115,630,838.48, an increase of 5.55% from the end of the previous year[4] - Total liabilities as of Q3 2021 amounted to ¥1,225,625,458.81, an increase from ¥1,162,211,826.93 in the previous year[28] - Current liabilities totaled ¥991,456,016.92, compared to ¥877,231,313.76 in Q3 2020, reflecting a growth of 13.0%[28] - Non-current liabilities decreased to ¥234,169,441.89 from ¥284,980,513.17 year-over-year, a decline of 17.8%[28] - The company's total equity was ¥2,592,000,000.00, with a capital reserve of ¥967,298,616.30, up from ¥963,095,015.97 in the previous year[28] Cash Flow - Cash flow from operating activities for the year-to-date was ¥216,285,018.38, a decrease of 12.37% compared to the same period last year[3] - The company reported a cash flow from operating activities of ¥319,799,858.54 for Q3 2021, compared to ¥286,304,422.09 in the same period last year[29] - The net cash flow from operating activities for the current period is ¥216,285,018.38, a decrease of 12.3% compared to ¥246,818,803.70 in the previous period[33] - The total cash inflow from investment activities is ¥669,876,764.38, down from ¥780,244,942.37 in the previous period, reflecting a decrease of 14.1%[33] - The net cash flow from financing activities is -¥92,423,177.27, an improvement from -¥184,643,873.65 in the previous period[34] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,631, with the top 10 shareholders holding a combined 56.73% of shares[12] - Li Shoujun, the largest shareholder, holds 41.42% of shares, totaling 167,474,479 shares, with 28,700,000 shares pledged[12] - The second-largest shareholder, Liang Wu, holds 5.87% of shares, totaling 23,716,898 shares[12] - The company has a total of 152,040,982 restricted shares at the end of the period, with no shares released during the reporting period[15] - The number of restricted shares held by Li Shoujun remains unchanged at 125,605,859 shares, locked until the end of the executive lock-up period[14] Business Segments - In the first three quarters of 2021, the company achieved operating revenue of CNY 1,498.95 million, a year-on-year increase of 2.58%[16] - The poultry business generated revenue of CNY 999.41 million, with a year-on-year increase of 1.44%[16] - The livestock business saw revenue of CNY 300.09 million, marking a significant year-on-year growth of 28.89%[16] - The pet business revenue reached CNY 19.45 million, reflecting a year-on-year increase of 15.16%[16] - The raw material drug business experienced a decline in revenue, totaling CNY 162.65 million, down 19.56% year-on-year[16] Research and Development - Research and development expenses increased to ¥85,769,408.06, up 17.6% from ¥72,899,951.48 in the same quarter last year[27] - The company is focusing on high-quality, comprehensive disease solutions to help clients reduce animal mortality rates and improve output[16] - The company has obtained new veterinary drug registration certificates and product approval numbers, enhancing its product line and market competitiveness[20] - The company is in the process of product transformation research and registration for the new antibiotic Tylosin derivative, which is expected to reduce bacterial resistance and expand the product line in the antibiotic sector[21] Market and Strategy - The company has not reported any new strategies or market expansions during this quarter[15] - There are no new products or technologies mentioned in the current report, focusing instead on existing shareholder structures and restrictions[15] - The demand for multi-category animal health products and one-stop services is increasing among large-scale livestock farmers due to complex farming environments and disease prevalence[16] - The company is accelerating external expansion and integration development to sustain rapid business growth[16] Miscellaneous - The company has not undergone an audit for the third quarter report[42] - The report indicates no adjustments made to prior comparative data under the new leasing standards[41] - The report was released by the board of directors on October 27, 2021[43]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 500 million RMB for the first half of 2021, representing a year-on-year growth of 25%[19]. - The company's operating revenue for the reporting period reached CNY 1,040,707,903.59, representing a 12.59% increase compared to CNY 924,328,191.06 in the same period last year[26]. - Net profit attributable to shareholders was CNY 203,585,329.13, up 38.21% from CNY 147,297,150.64 year-on-year[26]. - The total profit reached 253.43 million CNY, reflecting a year-on-year growth of 27.20%, while net profit attributable to shareholders was 203.59 million CNY, up 38.21% compared to the previous year[44]. - The net cash flow from operating activities was CNY 129,098,138.94, up 17.36% from CNY 110,001,441.60 in the same period last year[26]. - The asset-liability ratio stood at 31.65%, reflecting a solid balance sheet[44]. - Cash and cash equivalents increased by 100.55% to ¥149,598,930.71 from ¥74,592,577.87, reflecting improved cash flow management[72]. - The company reported a significant reduction in accounts receivable, decreasing by 15% compared to the previous period, improving cash flow[19]. - The company reported a total of 11,427.83 thousand yuan involved in six minor litigation cases, which do not significantly impact the company[131]. Market Expansion and Strategy - The company has provided a positive outlook for the second half of 2021, projecting a revenue growth of 20% to 30% compared to the first half[19]. - The company is actively pursuing market expansion, targeting a 10% increase in market share within the next year[19]. - A strategic acquisition of a smaller biotech firm is in progress, which is anticipated to enhance the company's R&D capabilities and product offerings[19]. - The company aims to enhance its market presence through multi-channel sales strategies, including direct sales, distributor channels, and government tenders[42]. - The company is focused on expanding its market reach by developing new feed additives and nutritional supplements for pets[52]. - The company is actively pursuing opportunities for market expansion and potential acquisitions to strengthen its competitive position[52]. Research and Development - New product development includes the launch of two innovative vaccines, expected to contribute an additional 100 million RMB in revenue by the end of the year[19]. - The company is committed to enhancing its technological capabilities, with an investment of 50 million RMB allocated for R&D in the upcoming year[19]. - The company has developed over 20 core technologies in animal health product R&D, including antibiotic crystalline structure technology and gene engineering technology[48]. - The company is focused on maintaining high standards in product quality and regulatory compliance, as demonstrated by its recent product registrations[52]. - The company has established strategic partnerships with over 30 renowned research institutions, enhancing its innovation capabilities through collaborative projects[65]. - The company has integrated a product R&D management system to enhance collaboration across departments, focusing on customer needs and market orientation[59]. Product Portfolio and Innovation - The company operates in the animal health industry, focusing on veterinary biological products, veterinary pharmaceuticals, and functional additives, with over 280 animal health products across more than 40 disease areas[39]. - The product line includes nearly 170 chemical drugs, over 60 biological products, and around 30 feed additives, showcasing a diverse portfolio[39]. - The company introduced a new product, a controlled-release formulation of Tilmicosin, enhancing its product portfolio in veterinary medicine[52]. - The company has established five product combinations in the livestock sector and six in the poultry sector, enhancing customer satisfaction through precise product solutions and lean value-added services[58]. - The company has established multiple innovative platforms for vaccine development, including high-density fermentation technology and new adjuvant development technology[66]. Risk Management - The company has identified and is addressing risks related to human resources and product development, ensuring robust risk management strategies are in place[6]. - The company faced risks related to human resources, product development, accounts receivable, and animal epidemics, implementing strategies to mitigate these risks[98][99][101]. Shareholder and Corporate Governance - No cash dividends or stock bonuses will be distributed to shareholders for this fiscal year, as the company aims to reinvest profits into growth initiatives[6]. - The company did not distribute cash dividends or bonus shares for the half-year period[107]. - The annual shareholders' meeting had a participation rate of 62.42%, while the first extraordinary shareholders' meeting had a participation rate of 50.80%[105]. - The company has not engaged in derivative investments during the reporting period[93]. - The company has no significant equity investments during the reporting period[86]. Social Responsibility and Compliance - In the first half of 2021, the company donated a total of 978,199.93 CNY to various social responsibility initiatives, including education and poverty alleviation[122]. - The company reported no administrative penalties related to environmental issues during the reporting period, indicating compliance with environmental regulations[122]. - The company has completed the construction and operation of pollution control facilities, with all systems functioning normally[118].

证券代码：300119 证券简称：瑞普生物 公告编号：2021-083 天津瑞普生物技术股份有限公司 关于举行投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司（以下简称"公司"）为便于广大投资者更 深入全面地了解公司情况，公司定于 2021 年 05 月 19 日（周三）15:00-16:30 在全景网举办"天津辖区网上集体接待日活动"。 本次活动将采用网络远程的方式举行，投资者可登录"全景•路演天下" （ http://rs.p5w.net）参与本次互动交流。出席本次活动的人员有：董事长、 总经理李守军先生，董事会秘书徐健女士。 欢迎广大投资者积极参与。 特此公告。 天津瑞普生物技术股份有限公司 董事会 二〇二一年五月十日 ...